申请人:Wynne Graham Michael
公开号:US20100048660A1
公开(公告)日:2010-02-25
There are disclosed compound of Formula (I) or (II) wherein A
1
, A
2
, A
3
, A
4
and A
5
, which may be the same or different, represent N or CR
1
, R
9
represents -L-R
3
, in which L is a single bond or a linker group and R
3
represents hydrogen or a substituent and in addition, when an adjacent pair of A
1
-A
4
each represent CR
1
, then the adjacent carbon atoms, together with their substituents may form a ring B, when A
5
represents CR
1
, then A
5
and N—R
9
, together with their substituents may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.
公开了化合物的式子(I)或(II),其中A1、A2、A3、A4和A5,可以相同也可以不同,代表N或CR1,R9代表-L-R3,其中L是单键或连接基团,R3代表氢或取代基团,此外,当相邻的A1-A4成对代表CR1时,它们相邻的碳原子及其取代基团可以形成环B,当A5代表CR1时,A5和N—R9及其取代基团可以形成环C,或其药学上可接受的盐,在制造用于治疗和/或预防杜兴肌肉萎缩症、贝克肌肉萎缩症或消瘦症的药物中使用。